This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2022 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.75% per year. These returns cover a period from January 1, 1988 through May 2, 2022. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News for PFE
FDA Recommends Adding New Omicron Subvariants to COVID Boosters
Is Trending Stock Pfizer Inc. (PFE) a Buy Now?
PFE: What are Zacks experts saying now?
Zacks Private Portfolio Services
The Zacks Analyst Blog Highlights Sanofi, Merck, Novartis, Pfizer and J&J
Pfizer (PFE) Inks Deal With US Government for COVID Jab Supply
Pharma Stock Roundup: FDA Panel Backs Updated COVID Jabs, EU Nod for SNY, MRK Drugs
Other News for PFE
My 26 Stock $336k Portfolio Outperforms The Market In Horrendous June Because Of This Key Trade
Pfizer Has Big Plans for Paxlovid
NEW YORK MARKET CLOSE: S&P 500 posts worst half-year fall since 1970
White House says big U.S. hospitals, health companies pledge to cut greenhouse gases
PFE Stock Rises as Pfizer Requests FDA Approval of Covid-19 Treatment Paxlovid